In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the ...

The Food and Drug Administration (FDA) announced the first-ever approval of an Ebola drug, which is made of three monoclonal antibodies. The drug, Inmazeb, was developed by Regeneron Pharmaceuticals ...

Scientists at La Jolla Institute for Immunology (LJI) have uncovered the structure and function of the first FDA-approved treatment for Zaire ebolavirus (Ebola virus). Inmazeb (REGN-EB3), developed by ...

The FDA has announced its first approval for an Ebola treatment that can be used with both pediatric and adult patients infected by Zaire ebolavirus. The treatment is called Inmazeb; it is comprised ...

Regeneron’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn combination) has been approved as the first treatment for Zaire ebolavirus (Ebola virus) infection in adults and children. The therapy ...

Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y., Oct. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ ...

Inmazeb is the first FDA-approved treatment for Zaire ebolavirus In keeping with our mission and values, Regeneron is committed to making this important medicine available to the people who need it.